{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:53:12Z","timestamp":1780318392823,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012326","name":"International Science and Technology Cooperation Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107877","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T06:23:21Z","timestamp":1728541401000},"page":"107877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of novel aza-stilbenes as a new class of selective MAO-B inhibitors for the treatment of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"153","author":[{"given":"Damijan","family":"Knez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xiang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Hrast Rambaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislav","family":"Gobec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-0219","authenticated-orcid":false,"given":"Chun-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-5537","authenticated-orcid":false,"given":"Rok","family":"Frlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0005","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/01.WNL.0000140706.52798.BE","article-title":"Incidence of Parkinsonism and Parkinson Disease in a General Population: The Rotterdam Study","volume":"63","author":"De Lau","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mds.27114","article-title":"The Future Burden of Parkinson\u2019s Disease","volume":"33","author":"Rocca","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bioorg.2024.107877_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.973310","article-title":"The Long-Term Trend of Parkinson\u2019s Disease Incidence and Mortality in China and a Bayesian Projection from 2020 to 2030","volume":"14","author":"Chen","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/01.wnl.0000271777.50910.73","article-title":"Projected Number of People With Parkinson Disease in the Most Populous Nations, 2005 Through 2030","volume":"69","author":"Calabrese","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.bioorg.2024.107877_b0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fnagi.2020.00004","article-title":"Strategies for the Treatment of Parkinson\u2019s Disease: Beyond Dopamine","volume":"12","author":"Iarkov","year":"2020","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0030","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/mds.27913","article-title":"Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson\u2019s Disease: A Systematic Review","volume":"35","author":"Delgado-Alvarado","year":"2020","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107877_b0035","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s Disease: Etiopathogenesis and Treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0040","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","article-title":"Pharmacological Aspects of the Neuroprotective Effects of Irreversible MAO-B Inhibitors, Selegiline and Rasagiline Parkinson\u2019s Disease","volume":"125","author":"Sz\u00f6k\u0151","year":"2018","journal-title":"J. Neural. Transm. (Vienna)"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107877_b0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The Therapeutic Potential of Monoamine Oxidase Inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0050","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00702-018-1881-5","article-title":"90 Years of Monoamine Oxidase: Some Progress and Some Confusion","volume":"125","author":"Tipton","year":"2018","journal-title":"J. Neural Transm."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0055","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","article-title":"Monoamine Oxidase Inhibitors, and Iron Chelators in Depressive Illness and Neurodegenerative Diseases","volume":"125","author":"Youdim","year":"2018","journal-title":"J. Neural Transm."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1385\/MN:30:1:077","article-title":"Perspectives on MAO-B in Aging and Neurological Disease: Where Do We Go from Here?","volume":"30","author":"Kumar","year":"2004","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107877_b0065","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and Treatment of Parkinson Disease: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"7466","key":"10.1016\/j.bioorg.2024.107877_b0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.38184.606169.AE","article-title":"Monoamine Oxidase Type B Inhibitors in Early Parkinson\u2019s Disease: Meta-Analysis of 17 Randomised Trials Involving 3525 Patients","volume":"329","author":"Ives","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2024.107877_b0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged Scaffolds as MAO Inhibitors: Retrospect and Prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0080","doi-asserted-by":"crossref","first-page":"eaav0316","DOI":"10.1126\/sciadv.aav0316","article-title":"Newly Developed Reversible MAO-B Inhibitor Circumvents the Shortcomings of Irreversible Inhibitors in Alzheimer\u2019s Disease","volume":"5","author":"Park","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2024.107877_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216188","article-title":"Monoamine Oxidase A (MAOA): A Promising Target for Prostate Cancer Therapy","volume":"563","author":"Han","year":"2023","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107877_b0090","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/med.21561","article-title":"Monoamine Oxidase-B Inhibitors as Potential Neurotherapeutic Agents: An Overview and Update","volume":"39","author":"Tripathi","year":"2019","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107877_b0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/1871527316666170124165222","article-title":"Monoamine Oxidase B Inhibitors in Parkinson\u2019s Disease","volume":"16","author":"Dezsi","year":"2017","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0100","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1021\/jm501722s","article-title":"Novel Arylalkenylpropargylamines as Neuroprotective, Potent, and Selective Monoamine Oxidase B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"58","author":"Huleatt","year":"2015","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107877_b0105","first-page":"622","article-title":"Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease","volume":"42","author":"Cruz","year":"2017","journal-title":"P T"},{"key":"10.1016\/j.bioorg.2024.107877_b0110","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2147\/DDDT.S302673","article-title":"The Current Evidence for the Use of Safinamide for the Treatment of Parkinson\u2019s Disease","volume":"15","author":"Abbruzzese","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2024.107877_b0115","article-title":"Recent Updates on Structural Insights of MAO-B Inhibitors: A Review on Target-Based Approach","author":"Baweja","year":"2023","journal-title":"Mol. Divers."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107877_b0120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/17460441.2019.1637415","article-title":"Novel Approaches to the Discovery of Selective Human Monoamine Oxidase-B Inhibitors: Is There Room for Improvement?","volume":"14","author":"Guglielmi","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2024.107877_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114655","article-title":"Monoamine Oxidase Inhibitors: A Concise Review with Special Emphasis on Structure Activity Relationship Studies","volume":"242","author":"Bhawna","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115352","article-title":"Bioisosteric Replacement Based on 1,2,4-Oxadiazoles in the Discovery of 1H-Indazole-Bearing Neuroprotective MAO B Inhibitors","volume":"255","author":"Rullo","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial","volume":"74","author":"Schapira","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bioorg.2024.107877_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103707","article-title":"Pyridoxine-Resveratrol Hybrids as Novel Inhibitors of MAO-B with Antioxidant and Neuroprotective Activities for the Treatment of Parkinson\u2019s Disease","volume":"97","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0145","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/ph15091152","article-title":"Development of Halogenated-Chalcones Bearing with Dimethoxy Phenyl Head as Monoamine Oxidase-B Inhibitors","volume":"15","author":"Rehuman","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"17","key":"10.1016\/j.bioorg.2024.107877_b0150","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1021\/jm501690r","article-title":"New Frontiers in Selective Human MAO-B Inhibitors","volume":"58","author":"Carradori","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopha.2018.06.064","article-title":"Imidazole Bearing Chalcones as a New Class of Monoamine Oxidase Inhibitors","volume":"106","author":"Sasidharan","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0160","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1021\/acsomega.2c07694","article-title":"Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson\u2019s Disorder","volume":"8","author":"Kumar","year":"2023","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0165","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/ph14111148","article-title":"Replacement of Chalcone-Ethers with Chalcone-Thioethers as Potent and Highly Selective Monoamine Oxidase-B Inhibitors and Their Protein-Ligand Interactions","volume":"14","author":"Mathew","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/14756366.2020.1842390","article-title":"Morpholine-Based Chalcones as Dual-Acting Monoamine Oxidase-B and Acetylcholinesterase Inhibitors: Synthesis and Biochemical Investigations","volume":"36","author":"Sasidharan","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0175","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14238","article-title":"Exploration of a New Class of Monoamine Oxidase B Inhibitors by Assembling Benzyloxy Pharmacophore on Halogenated Chalcones","volume":"102","author":"Singh","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"issue":"42","key":"10.1016\/j.bioorg.2024.107877_b0180","doi-asserted-by":"crossref","first-page":"28182","DOI":"10.1021\/acsomega.1c04252","article-title":"Halogenated Coumarin-Chalcones as Multifunctional Monoamine Oxidase-B and Butyrylcholinesterase Inhibitors","volume":"6","author":"Rehuman","year":"2021","journal-title":"ACS Omega"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0185","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3390\/molecules26092430","article-title":"Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies","volume":"26","author":"Moya-Alvarado","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0190","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1007\/s11064-020-03130-y","article-title":"Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson\u2019s Disease","volume":"45","author":"Parambi","year":"2020","journal-title":"Neurochem. Res."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107877_b0195","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3390\/molecules25102356","article-title":"Novel Class of Chalcone Oxime Ethers as Potent Monoamine Oxidase-B and Acetylcholinesterase Inhibitors","volume":"25","author":"Oh","year":"2020","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.bioorg.2024.107877_b0200","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/cmdc.202000305","article-title":"A New Potent and Selective Monoamine Oxidase-B Inhibitor with Extended Conjugation in a Chalcone Framework: 1-[4-(Morpholin-4-yl)Phenyl]-5-phenylpenta-2,4-dien-1-one","volume":"15","author":"Maliyakkal","year":"2020","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0205","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1080\/14756366.2020.1797711","article-title":"Design, Synthesis, and Evaluation of 1, 4-Benzodioxan-Substituted Chalcones as Selective and Reversible Inhibitors of Human Monoamine Oxidase B","volume":"35","author":"Kong","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0210","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijbiomac.2019.06.167","article-title":"Potent and Selective Inhibition of Human Monoamine Oxidase-B by 4-Dimethylaminochalcone and Selected Chalcone Derivatives","volume":"137","author":"Oh","year":"2019","journal-title":"Int. J. Bio Macromol."},{"key":"10.1016\/j.bioorg.2024.107877_b0215","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijbiomac.2017.11.159","article-title":"Discovery of Potent and Reversible MAO-B Inhibitors as Furanochalcones","volume":"108","author":"Suresh","year":"2018","journal-title":"Int. J. Bio Macromol."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0220","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/acsmedchemlett.1c00238","article-title":"Promising Non-Cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B","volume":"12","author":"Iacovino","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107877_b0225","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/antiox10101641","article-title":"Highly Potent, Selective, and Competitive Indole-Based MAO-B Inhibitors Protect PC12 Cells against 6-Hydroxydopamine- and Rotenone-Induced Oxidative Stress","volume":"10","author":"Elsherbeny","year":"2021","journal-title":"Antioxidants (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0230","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1080\/14756366.2020.1800666","article-title":"Discovery of N-(1-(3-Fluorobenzoyl)-1H-Indol-5-Yl)Pyrazine-2-Carboxamide: A Novel, Selective, and Competitive Indole-Based Lead Inhibitor for Human Monoamine Oxidase B","volume":"35","author":"Elkamhawy","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0235","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00044-019-02388-4","article-title":"Novel Isoxazole Derivatives as Potential Antiparkinson Agents: Synthesis, Evaluation of Monoamine Oxidase Inhibitory Activity and Docking Studies","volume":"28","author":"Agrawal","year":"2019","journal-title":"Med. Chem. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107877_b0240","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.21873\/anticanres.17040","article-title":"Non-Cytotoxic 3-Acetylcoumarin as an Attractive Target for Human Monoamine Oxidase (HMAO) Enzymes","volume":"44","author":"Aghimien","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bioorg.2024.107877_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103986","article-title":"Discovery and Optimization of 3-Thiophenylcoumarins as Novel Agents against Parkinson\u2019s Disease: Synthesis, in Vitro and in Vivo Studies","volume":"101","author":"Rodr\u00edguez-Enr\u00edquez","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104203","article-title":"Novel Coumarin-Pyridazine Hybrids as Selective MAO-B Inhibitors for the Parkinson\u2019s Disease Therapy","volume":"104","author":"Rodr\u00edguez-Enr\u00edquez","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104685","article-title":"Design and Synthesis of Novel 3,4-Dihydrocoumarins as Potent and Selective Monoamine Oxidase-B Inhibitors with the Neuroprotection against Parkinson\u2019s Disease","volume":"109","author":"Liu","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0260","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acsmedchemlett.2c00001","article-title":"Dual Reversible Coumarin Inhibitors Mutually Bound to Monoamine Oxidase B and Acetylcholinesterase Crystal Structures","volume":"13","author":"Ekstr\u00f6m","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0265","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1039\/C8MD00399H","article-title":"Selected Aryl Thiosemicarbazones as a New Class of Multi-Targeted Monoamine Oxidase Inhibitors","volume":"9","author":"Mathew","year":"2018","journal-title":"Med. Chem. Commun."},{"issue":"13","key":"10.1016\/j.bioorg.2024.107877_b0270","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1080\/07391102.2020.1782266","article-title":"Development of Methylthiosemicarbazones as New Reversible Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease","volume":"39","author":"Mathew","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2024.107877_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104917","article-title":"Novel 2,5-Disubstituted-1,3,4-Oxadiazole Derivatives as MAO-B Inhibitors: Synthesis, Biological Evaluation and Molecular Modeling Studies","volume":"112","author":"Tok","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0280","first-page":"1","article-title":"Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson\u2019s Disease: Past, Present, and Future","author":"Tan","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bioorg.2024.107877_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127966","article-title":"Mur Ligases Inhibitors with Azastilbene Scaffold: Expanding the Structure-Activity Relationship","volume":"40","author":"Hrast","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0290","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acs.jmedchem.9b01886","article-title":"Stereoselective Activity of 1-Propargyl-4-Styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B","volume":"63","author":"Knez","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107877_b0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/BMC.2011.030","article-title":"Structures and Mechanism of the Monoamine Oxidase Family","volume":"2","author":"Gaweska","year":"2011","journal-title":"Biomol. Concepts"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0300","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1093\/brain\/awac096","article-title":"Reimagining Cholinergic Therapy for Alzheimer\u2019s Disease","volume":"145","author":"Giacobini","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.bioorg.2024.107877_b0305","first-page":"1","article-title":"Characterization, Bioactivity, Encapsulation and Structural Modifications. A Review of Their Current Limitations and Promising Approaches","author":"Navarro-Orcajada","year":"2022","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.bioorg.2024.107877_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/274643","article-title":"Azastilbene Analogs as Tyrosinase Inhibitors: New Molecules with Depigmenting Potential","volume":"2013","author":"Lima","year":"2013","journal-title":"Sci. World J."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107877_b0315","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s10637-011-9749-7","article-title":"Aza-Derivatives of Resveratrol Are Potent Macrophage Migration Inhibitory Factor Inhibitors","volume":"30","author":"Fujita","year":"2012","journal-title":"Invest. New Drugs"},{"issue":"27","key":"10.1016\/j.bioorg.2024.107877_b0320","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1039\/c3ob27449g","article-title":"Azastilbenes: A Cut-off to P38 MAPK Inhibitors","volume":"11","author":"Poon","year":"2013","journal-title":"Org. Biomol. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0325","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1007\/s00044-020-02585-6","article-title":"Synthesis, Radical Scavenging, and Antioxidant Activity of Stilbazolic Resveratrol Analogs","volume":"29","author":"Semenov","year":"2020","journal-title":"Med. Chem. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0330","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/abio.1997.2391","article-title":"A Stable Nonfluorescent Derivative of Resorufin for the Fluorometric Determination of Trace Hydrogen Peroxide: Applications in Detecting the Activity of Phagocyte NADPH Oxidase and Other Oxidases","volume":"253","author":"Zhou","year":"1997","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0335","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0340","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/acscentsci.7b00069","article-title":"The Ecstasy and Agony of Assay Interference Compounds","volume":"3","author":"Aldrich","year":"2017","journal-title":"ACS Cent. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107877_b0345","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.drudis.2022.03.008","article-title":"Redox Active or Thiol Reactive? Optimization of Rapid Screens to Identify Less Evident Nuisance Compounds","volume":"27","author":"Proj","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"20","key":"10.1016\/j.bioorg.2024.107877_b0350","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/cmdc.201900395","article-title":"Identification of Compounds That Interfere with High-Throughput Screening Assay Technologies","volume":"14","author":"David","year":"2019","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107877_b0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12154-011-0055-9","article-title":"Hill Coefficients of Dietary Polyphenolic Enzyme Inhibitiors: Can Beneficial Health Effects of Dietary Polyphenols Be Explained by Allosteric Enzyme Denaturing?","volume":"4","author":"Kuhnert","year":"2011","journal-title":"J. Chem. Biol."},{"key":"10.1016\/j.bioorg.2024.107877_b0360","series-title":"A Guide for Medicinal Chemists and Pharmacologists","article-title":"Evaluation of Enzyme Inhibitors in Drug Discovery","author":"Copeland","year":"2013"},{"issue":"11","key":"10.1016\/j.bioorg.2024.107877_b0365","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00702-018-1915-z","article-title":"The Structure of Monoamine Oxidases: Past, Present, and Future","volume":"125","author":"Iacovino","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0370","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A Perspective on Multi-target Drug Discovery and Design for Complex Diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0375","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/17460441.2014.932346","article-title":"What Does the Aromatic Ring Number Mean for Drug Design?","volume":"9","author":"Ward","year":"2014","journal-title":"Expert Opin. Drug Discov."},{"issue":"3\u20134","key":"10.1016\/j.bioorg.2024.107877_b0380","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drudis.2010.11.014","article-title":"The Impact of Aromatic Ring Count on Compound Developability: Further Insights by Examining Carbo- and Hetero-Aromatic and -Aliphatic Ring Types","volume":"16","author":"Ritchie","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107877_b0385","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.apsb.2019.05.004","article-title":"Structural Simplification: An Efficient Strategy in Lead Optimization","volume":"9","author":"Wang","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0390","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/tx200211v","article-title":"Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety","volume":"24","author":"Meanwell","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107877_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112911","article-title":"Pyrimido[1,2-b]Indazole Derivatives: Selective Inhibitors of Human Monoamine Oxidase B with Neuroprotective Activity","volume":"209","author":"Jismy","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107877_b0400","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","article-title":"Current Place of Monoamine Oxidase Inhibitors in the Treatment of Depression","volume":"27","author":"Shulman","year":"2013","journal-title":"CNS Drugs"},{"issue":"23","key":"10.1016\/j.bioorg.2024.107877_b0405","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of Human Monoamine Oxidase B Complexes with Selective Noncovalent Inhibitors: Safinamide and Coumarin Analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2024.107877_b0410","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein\u2212Ligand Complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0415","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107877_b0420","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107877_b0425","unstructured":"Schr\u00f6dinger Release 2022-1: Glide, Schr\u00f6dinger, LLC, New York, NY, 2021."},{"key":"10.1016\/j.bioorg.2024.107877_b0430","unstructured":"Schr\u00f6dinger Release 2023-1: LigPrep, Schr\u00f6dinger, LLC, New York, NY, 2021."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107877_b0435","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1021\/acs.jmedchem.8b00357","article-title":"Tight-Binding Inhibition of Human Monoamine Oxidase B by Chromone Analogs: A Kinetic, Crystallographic, and Biological Analysis","volume":"61","author":"Reis","year":"2018","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107877_b0440","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bmc.2016.11.032","article-title":"N-Propargylpiperidines with Naphthalene-2-Carboxamide or Naphthalene-2-Sulfonamide Moieties: Potential Multifunctional Anti-Alzheimer\u2019s Agents","volume":"25","author":"Ko\u0161ak","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2024.107877_b0445","doi-asserted-by":"crossref","first-page":"e202200456","DOI":"10.1002\/cbic.202200456","article-title":"Grid-Type Quaternary Metallosupramolecular Compounds Inhibit Human Cholinesterases through Dynamic Multivalent Interactions","volume":"23","author":"Nachon","year":"2022","journal-title":"Chembiochem"},{"key":"10.1016\/j.bioorg.2024.107877_b0450","first-page":"227","article-title":"Prepustnost krvno-mo\u017eganske pregrade pri razvoju u\u010dinkovin z delovanjem v osrednjem \u017eiv\u010devju","volume":"3","author":"Knez","year":"2014","journal-title":"Farm. Vestn."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2024.107877_b0455","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2024.107877_b0460","unstructured":"Schr\u00f6dinger Release 2022-1: QikProp, Schr\u00f6dinger, LLC, New York, NY, 2021."},{"key":"10.1016\/j.bioorg.2024.107877_b0465","doi-asserted-by":"crossref","unstructured":"Copeland, R. A. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 1st Ed.; Wiley, 2000. Doi: 10.1002\/0471220639.","DOI":"10.1002\/0471220639"},{"key":"10.1016\/j.bioorg.2024.107877_b0470","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.neuroscience.2017.11.040","article-title":"Serum Response Factor Promotes Dopaminergic Neuron Survival via Activation of Beclin 1-Dependent Autophagy","volume":"371","author":"Cheng","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.bioorg.2024.107877_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112924","article-title":"Cell Models for Alzheimer\u2019s and Parkinson\u2019s Disease: At the Interface of Biology and Drug Discovery","volume":"149","author":"Cetin","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107877_b0480","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/biomedicines9080918","article-title":"Oxidative Stress, Mitochondrial Dysfunction, and Neuroprotection of Polyphenols with Respect to Resveratrol in Parkinson\u2019s Disease","volume":"9","author":"Kung","year":"2021","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107877_b0485","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1096\/fj.201901565RR","article-title":"BMAL1 Regulation of Microglia-mediated Neuroinflammation in MPTP-induced Parkinson\u2019s Disease Mouse Model","volume":"34","author":"Liu","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2024.107877_b0490","doi-asserted-by":"crossref","unstructured":"Von der Eltz H.; Guder H.-J.; Muhlegger K. New Hydrolase Substrates. U.S. Patent. No. 4,900,822, February 13, 1990.","DOI":"10.1007\/BF03349649"},{"key":"10.1016\/j.bioorg.2024.107877_b0495","unstructured":"Schr\u00f6dinger Release 2023-1: Maestro, Schr\u00f6dinger, LLC, New York, NY, 2021."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107877_b0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An Open Chemical Toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Cheminf."},{"key":"10.1016\/j.bioorg.2024.107877_b0505","unstructured":"OMEGA 4.1.2.0: OpenEye Scientific Software, Santa Fe, NM. http:\/\/www.Eyesopen.Com."},{"key":"10.1016\/j.bioorg.2024.107877_b0510","unstructured":"BIOVIA, Dassault Syst\u00e8mes, Discovery Studio Visualizer, V21.1.0.20298, San Diego: Dassault Syst\u00e8mes, 2020."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107877_b0515","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/gerona\/glab253","article-title":"Early-Life Stress Induces Prodromal Features of Parkinsonism in Ageing Rats","volume":"77","author":"Ren","year":"2022","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682400782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682400782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:25:43Z","timestamp":1738203943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682400782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":103,"alternative-id":["S004520682400782X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107877","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel aza-stilbenes as a new class of selective MAO-B inhibitors for the treatment of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107877","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107877"}}